The American Diabetes Association (ADA)“Standards of Care in Diabetes” includes the
ADA's current clinical practice recommendations and is intended to provide the components …

Objective To provide evidence-based recommendations regarding the diagnosis and
management of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis …

Find AGA's NASH Clinical Care Pathway App for iOS and Android mobile devices at nash.
gastro. org. Scan this QR code to be taken directly to the website. Nonalcoholic fatty liver …

Metabolic associated fatty liver disease (MAFLD) is the principal worldwide cause of liver
disease and affects nearly a quarter of the global population. The objective of this work was …

Metabolic dysfunction-associated steatotic liver disease (MASLD) is the latest term for
steatotic liver disease associated with metabolic syndrome. MASLD is the most common …

Chronic liver disease (CLD) is associated with approximately two million annual deaths
worldwide and is an enormous health burden.[1, 2] The majority of liver-related outcomes …

Liver fibrosis should be assessed in all individuals with chronic liver disease as it predicts
the risk of future liver-related morbidity and thus need for treatment, monitoring and …

The American Diabetes Association (ADA)“Standards of Care in Diabetes” includes the
ADA's current clinical practice recommendations and is intended to provide the components …

Non‐alcoholic fatty liver disease (NAFLD) affects at least 25% of the general population and
is an increasingly important cause of cirrhosis and hepatocellular carcinoma. Although it is …

Nonalcoholic fatty liver disease (NAFLD) encompasses a spectrum of liver conditions that
are characterized by excess accumulation of fat in the liver, and is diagnosed after exclusion …